Background Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune,
inflammatory disorder that typically affects the optic nerves and spinal cord. At least two thirds …

Prevention of irreversible disability is currently the most important goal of disease modifying
therapy for multiple sclerosis. The disability outcomes used in most clinical trials rely on …

Importance Within 2 decades of onset, 80% of untreated patients with relapsing-remitting
multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary …

In the modern world, people are exposed to electromagnetic fields (EMFs) as part of their
daily lives; the important question is “What is the effect of EMFs on human health?” Most …

Background Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than
interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy …

Objective In patients suffering multiple sclerosis activity despite treatment with interferon β
or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. …

Background There is an unmet need to develop therapeutic interventions directed at the
neurodegeneration that underlies progression in multiple sclerosis. High-dose, pharmaceutical-…

Background: Demyelinating lesions over 20 mm in size, referred to as tumefactive demyelinating
lesions, can be misdiagnosed as being either a tumor or an abscess. Although some …

Importance After multiple sclerosis (MS) relapse while a patient is receiving an injectable
disease-modifying drug, many physicians advocate therapy switch, but the relative …

Non-steroidal anti-inflammatory drugs (NSAIDs) have been in use for many years and
constitute a large part of prescriptions issued in daily practice. Although NSAIDs are used for …